Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.66 |
| ▸ | CA2 | P00918 | 3/20 | 0.66 |
| ▸ | CA9 | Q16790 | 2/20 | 0.66 |
| ▸ | CA12 | O43570 | 1/20 | 0.66 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | CA4 | P22748 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | PARK7 | Q99497 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31667432 | 0.84 | ENPP2 (0.51) | CA1CA2CA9CA12ENPP2 | |
| SCHEMBL12104396 | 0.84 | CA12 (0.65) | CA1CA2CA9CA12ENPP2 | |
| SCHEMBL31667423 | 0.83 | ESR1 (0.59) | CA1CA2CA9CA12ENPP2 | |
| SCHEMBL31667378 | 0.82 | CASP3 (0.63) | CA1CA2CA9CA12MEN1 | |
| SCHEMBL16369831 | 0.81 | CA1 (0.61) | CA1CA2CA9CA12ENPP2 | |
| SCHEMBL31667405 | 0.81 | CASP3 (0.58) | CA1CA2CA9CA12ACHE | |
| SCHEMBL31667571 | 0.81 | MEN1 (0.48) | CA1CA2CA9CA12ENPP2 | |
| SCHEMBL14047967 | 0.81 | ACHE (0.75) | MEN1KMT2AACHETP53MAPT | |
| SCHEMBL31667181 | 0.81 | CA9 (0.68) | CA1CA2CA9CA12ENPP2 | |
| SCHEMBL18669025 | 0.80 | CASP3 (0.62) | CA1CA2CA9CA12MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078130-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | SIRONAX LTD (KY) | 2026-03-19 | — | — | US | disclosed |
| EP-4590674-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd (KY) | 2025-07-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078130-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | NAMPT, NNMT, SARM1 | CA1 4427/4885CA2 3432/4885CA9 4407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.